SCHEMBL8737

SCHEMBL8737

Cc1ccccc1-c1cc(C=O)c(N)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
TSHR P16473 3/20 0.42
CYP1A2 P05177 10/20 0.41
CYP2D6 P10635 6/20 0.41
CYP2C19 P33261 6/20 0.41
CLK4 Q9HAZ1 5/20 0.41
CYP3A4 P08684 5/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
ALOX15 P16050 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
APAF1 O14727 1/20 0.41
NPC1 O15118 1/20 0.41
TDP2 O95551 1/20 0.41
PKM P14618 1/20 0.41
MAOB P27338 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10929 0.78 LCK (0.41) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL9652 0.72 NPC1 (0.42) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL2004558 0.71 IDO1 (0.42) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL14327941 0.71 UHRF1 (0.54) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL16716059 0.71 CYP1A2 (0.51) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL3424160 0.70 IDO1 (0.55) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL25293042 0.70 CYP1A2 (0.44) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL30479920 0.70 CYP1A2 (0.44) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL30479917 0.70 CYP1A2 (0.44) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19
SCHEMBL2187672 0.70 CYP1A2 (0.50) ALDH1A1TSHRCYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 US disclosed
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use AMGEN INC. (US) 2012-12-27 US disclosed
EP-2504315-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2012-10-03 EP disclosed
WO-2011063233-A1 AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329830-A1 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use BACE1, BACE2, APP ALDH1A1 1846/4885TSHR 3276/4885CYP1A2 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.